Cancer Research and Treatment

BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer

Caroline Stahnke Richau, Nicole de Miranda Scherer, Bruna Palma Matta, Elvismary Molina de Armas, Fábio Carvalho de Barros Moreira, Anke Bergmann, Claudia Bessa Pereira Chaves, Mariana Boroni, Anna Claudia Evangelista dos Santos, Miguel Angelo Martins Mor

T-Cell Receptor Repertoire Characteristics Associated with Prognostic Significance in High-Grade Serous Ovarian Carcinoma

Ju-Won Kim, Sewha Kim, So-Yun Yang, Je-Gun Joung, Sohyun Hwang

Potential prognostic role of somatic mutations in a set of cancer susceptibility genes in ovarian carcinoma: A follow-up multicentric study from Pakistan

Atika Masood, Rahat Sarfaraz, Saima Zaki, Amira Shami, Saba Khaliq, Nadia Naseem

Deleterious and ethnic-related BRCA1/2 mutations in tissue and blood of Egyptian colorectal cancer patients and its correlation with human papillomavirus

Amira Salah El-Din Youssef, Abdel Rahman N. Zekri, Marwa Mohanad, Samah A. Loutfy, Nasra F. Abdel Fattah, Mostafa H. Elberry, Asmaa A. El Leithy, Ahmed El-Touny, Ahmed Samy Rabie, Mohamed Shalaby, Ayman Hanafy, Mai M. Lotfy, Enas R. El-sisi, Gharieb S. El

Clinical and Experimental Medicine.2023; 23(8): 5063. CrossRef

SIK2 kinase synthetic lethality is driven by spindle assembly defects in FANCA‐deficient cells

Ka‐Kui Chan, Zahi Abdul‐Sater, Aditya Sheth, Dana K. Mitchell, Richa Sharma, Donna M. Edwards, Ying He, Grzegorz Nalepa, Steven D. Rhodes, D. Wade Clapp, Elizabeth A. Sierra Potchanant

Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047)

Jason K. Sa, Jihye Kim, Sokbom Kang, Sang Wun Kim, Taejong Song, Seung‐Hyuk Shim, Min Chul Choi, Jae Hong No, Jae‐Yun Song, Deokhoon Kim, Yong‐Man Kim, Jae‐Hoon Kim, Jeong‐Won Lee

International Journal of Cancer.2022; 151(7): 1086. CrossRef

Analysis of Novel Variants Associated with Three Human Ovarian Cancer Cell Lines

Venugopala Reddy Mekala, Jan-Gowth Chang, Ka-Lok Ng

Current Bioinformatics.2022; 17(4): 380. CrossRef

Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets

Alexandre André Balieiro Anastácio da Costa, Glauco Baiocchi

Seminars in Cancer Biology.2021; 77: 29. CrossRef

The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study

Angela Toss, Claudia Piombino, Elena Tenedini, Alessandra Bologna, Elisa Gasparini, Vittoria Tarantino, Maria Elisabetta Filieri, Luca Cottafavi, Filippo Giovanardi, Stefano Madrigali, Monica Civallero, Luigi Marcheselli, Isabella Marchi, Federica Domati,

USP19 and RPL23 as Candidate Prognostic Markers for Advanced-Stage High-Grade Serous Ovarian Carcinoma

Haeyoun Kang, Min Chul Choi, Sewha Kim, Ju-Yeon Jeong, Ah-Young Kwon, Tae-Hoen Kim, Gwangil Kim, Won Duk Joo, Hyun Park, Chan Lee, Seung Hun Song, Sang Geun Jung, Sohyun Hwang, Hee Jung An

Summary of BARD1 Mutations and Precise Estimation of Breast and Ovarian Cancer Risks Associated with the Mutations

Prevalence of pathogenic variants in actionable genes in advanced ovarian cancer: a next-generation sequencing analysis of a nationwide registry study

European Journal of Cancer.2020; 141: 185. CrossRef

PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality—An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness

Patrycja Gralewska, Arkadiusz Gajek, Agnieszka Marczak, Michał Mikuła, Jerzy Ostrowski, Agnieszka Śliwińska, Aneta Rogalska

International Journal of Molecular Sciences.2020; 21(24): 9715. CrossRef